<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02782026</url>
  </required_header>
  <id_info>
    <org_study_id>2014-01321-46</org_study_id>
    <nct_id>NCT02782026</nct_id>
  </id_info>
  <brief_title>Exhaled Breath Olfactory Signature of Pulmonary Arterial Hypertension</brief_title>
  <acronym>SNOOPY2</acronym>
  <official_title>Exhaled Breath Olfactory Signature of Pulmonary Arterial Hypertension Detected by an Artificial Nose: A Clinical Validation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technion, Israel Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective case-control study, the investigators will evaluate the diagnostic&#xD;
      performance of a novel electronic nose (E-nose) for the detection of Pulmonary Arterial&#xD;
      Hypertension (PAH). This study is designed to:&#xD;
&#xD;
        1. Assess the performance of the E-nose to discriminate controls from patients with PAH&#xD;
&#xD;
        2. Assess the performance of the E-nose to discriminate between different subtypes of&#xD;
           pulmonary hypertension (PH), namely idiopathic PAH, heritable PAH with BMPR2 mutation&#xD;
           and chronic thromboembolic PH&#xD;
&#xD;
        3. Assess the performance of the E-nose to discriminate controls from asymptomatic patients&#xD;
           with PH who carry BMPR2 mutations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary arterial hypertension (PAH) is a progressive and rare severe disease (prevalence of&#xD;
      15-50 per million) due to obstruction of small pulmonary arteries, leading to an increase in&#xD;
      pulmonary artery pressure with the ultimate consequence right heart failure. Despite recent&#xD;
      advances in therapeutic care, there is no cure and most patients die or require lung&#xD;
      transplantation within 5 years of diagnosis. Currently, right heart catheterisation is&#xD;
      required to diagnose PAH and monitor response to treatment. Right heart catheterisation is an&#xD;
      invasive test, and alternatives such as echocardiography have not yielded sufficient accuracy&#xD;
      both for early diagnosis and disease monitoring. Currently, PAH is often diagnosed at an&#xD;
      advanced stage of the disease. There is often a delay in diagnosis of several years between&#xD;
      the first symptoms and the identification of the disease due to the non-specific nature of&#xD;
      symptoms. Hence, there is the need to improve the time between the first signs and definitive&#xD;
      diagnosis of the disease. Early diagnosis of PAH remains a challenge due to the low&#xD;
      sensitivity and specificity of biomarkers available currently.&#xD;
&#xD;
      The main objective is to validate the results obtained in the previous preliminary proof of&#xD;
      concept study - that PAH patients display a unique olfactory signature that can be detected&#xD;
      by an artificial E- nose.&#xD;
&#xD;
      Secondary objectives are to investigate the ability of the E-nose to:&#xD;
&#xD;
        -  Discriminate patients with idiopathic PAH from those with heritable PAH due to BMPR2&#xD;
           mutations&#xD;
&#xD;
        -  Discriminate patients with chronic thromboembolic pulmonary hypertension (CTEPH) from&#xD;
           healthy controls, and patients with idiopathic and/or heritable PAH.&#xD;
&#xD;
        -  Detect development of PAH in BMPR2 mutation carriers&#xD;
&#xD;
        -  Determine whether the olfactory signature can stratify subgroups of patients by&#xD;
           correlating the olfactory signature to different biological and clinical parameters&#xD;
           (hemodynamic measurements, NYHA class, duration of treatment, 6-minute walk distance,&#xD;
           response to nitric oxide, BNP levels).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 4, 2016</start_date>
  <completion_date type="Actual">September 4, 2018</completion_date>
  <primary_completion_date type="Actual">August 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volatile organic compounds in exhaled breath in patients of each group detected using sensor array on the basis of cross-reactive gold-nanoparticles coated with organic ligands.</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>The primary endpoint will be the ability of the E-nose to discriminate patients with PAH from healthy controls by their olfactory signature from the profile of volatile organic compounds in exhaled breath.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">273</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>idiopathic PAH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exhaled Breath Olfactory Signature Detected by an Artificial Nose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>heritable PAH with BMPR2 mutation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exhaled Breath Olfactory Signature Detected by an Artificial Nose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chronic thromboembolic PH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exhaled Breath Olfactory Signature Detected by an Artificial Nose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exhaled Breath Olfactory Signature Detected by an Artificial Nose</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Exhaled Breath Olfactory Signature (Artificial Nose)</intervention_name>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>chronic thromboembolic PH</arm_group_label>
    <arm_group_label>heritable PAH with BMPR2 mutation</arm_group_label>
    <arm_group_label>idiopathic PAH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients group (Group A)&#xD;
&#xD;
          -  Age 18 to 65 years inclusive&#xD;
&#xD;
          -  Idiopathic or heritable PAH confirmed by right heart catheterization&#xD;
&#xD;
          -  Affiliated to a social security (excluding AME)&#xD;
&#xD;
        Healthy control group (Group B)&#xD;
&#xD;
          -  Age 18 to 65 years inclusive&#xD;
&#xD;
          -  No known allergy&#xD;
&#xD;
          -  No history of known pathology&#xD;
&#xD;
          -  No chronic disease in active phase&#xD;
&#xD;
          -  No history of respiratory illness&#xD;
&#xD;
          -  Not genetically linked with the patient&#xD;
&#xD;
          -  Affiliated to a social security (excluding AME)&#xD;
&#xD;
        At risk group (Group C)&#xD;
&#xD;
          -  Age between 18 and 65 years old inclusive&#xD;
&#xD;
          -  Subjects included in the protocol Delphi2 or Subject satisfying the inclusion and&#xD;
             non-inclusion criteria of the DELPHI2 study&#xD;
&#xD;
          -  Affiliated to a social security (excluding AME)&#xD;
&#xD;
        Patient group (Group D)&#xD;
&#xD;
          -  Age between 18 and 65 years old inclusive&#xD;
&#xD;
          -  Post-embolic HTP&#xD;
&#xD;
          -  Affiliated to a social security scheme (excluding AME)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any patient/subject presenting :&#xD;
&#xD;
          -  Connective tissue disease&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Portal hypertension&#xD;
&#xD;
          -  Congenital heart disease&#xD;
&#xD;
          -  Asthma and other coexisting lung diseases&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Alcohol addiction (if consumption &gt;3 glasses/day for men and &gt;2 glasses/day for women)&#xD;
&#xD;
          -  Smoking addiction (if consumption &gt;5 cigarettes/day)&#xD;
&#xD;
          -  Having had a CT scan in the week prior to the inclusion visit&#xD;
&#xD;
          -  Subjects who have consumed coffee, alcohol, or a cigarette in less than 3 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Humbert, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AP-HP, Bicêtre Hospital</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>February 23, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2016</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary hypertension</keyword>
  <keyword>early detection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

